Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study.

Cescon A, Patterson S, Chan K, Palmer AK, Margolese S, Burchell AN, Cooper C, Klein MB, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Raboud JM, Loutfy MR; CANOC Collaboration.

PLoS One. 2013 Dec 31;8(12):e83649. doi: 10.1371/journal.pone.0083649. eCollection 2013.

2.

Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history.

Cescon A, Chan K, Raboud JM, Burchell AN, Forrest JI, Klein MB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Cooper C; CANOC Collaboration.

AIDS. 2014 Jan 2;28(1):121-7. doi: 10.1097/QAD.0000000000000020.

PMID:
24413263
3.

Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.

Raboud J, Blitz S, Walmsley S, Thompson C, Rourke SB, Loutfy MR; Ontario HIV Treatment Network Cohort Study Team.

HIV Clin Trials. 2010 Nov-Dec;11(6):340-50. doi: 10.1310/hct1106-340.

PMID:
21239362
4.

Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.

Milloy MJ, Kerr T, Buxton J, Rhodes T, Krusi A, Guillemi S, Hogg R, Montaner J, Wood E.

J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):393-9. doi: 10.1097/QAI.0b013e3182433288.

5.

Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.

Nolan S, Milloy MJ, Zhang R, Kerr T, Hogg RS, Montaner JS, Wood E.

AIDS Care. 2011 Aug;23(8):980-7. doi: 10.1080/09540121.2010.543882.

PMID:
21480010
6.

Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort.

Tanner Z, Lachowsky N, Ding E, Samji H, Hull M, Cescon A, Patterson S, Chia J, Leslie A, Raboud J, Loutfy M, Cooper C, Klein M, Machouf N, Tsoukas C, Montaner J, Hogg RS; Canadian Observation Cohort (CANOC) Collaboration.

BMC Infect Dis. 2016 Oct 21;16(1):590.

7.

Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.

Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration.

PLoS Med. 2012;9(9):e1001304. Epub 2012 Sep 4.

8.

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.

May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte Ad, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):348-54. doi: 10.1097/QAI.0000000000000603.

9.

Frequency of Viremic Episodes in HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy: A Cohort Study.

Myer L, Dunning L, Lesosky M, Hsiao NY, Phillips T, Petro G, Zerbe A, McIntyre JA, Abrams EJ.

Clin Infect Dis. 2017 Feb 15;64(4):422-427. doi: 10.1093/cid/ciw792.

PMID:
27927852
10.

Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.

Raboud JM, Loutfy MR, Su D, Bayoumi AM, Klein MB, Cooper C, Machouf N, Rourke S, Walmsley S, Rachlis A, Harrigan PR, Smieja M, Tsoukas C, Montaner JS, Hogg RS; CANOC Collaboration.

BMC Infect Dis. 2010 Feb 25;10:40. doi: 10.1186/1471-2334-10-40.

11.

Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care.

Cescon A, Patterson S, Davey C, Ding E, Raboud JM, Chan K, Loutfy MR, Cooper C, Burchell AN, Palmer AK, Tsoukas C, Machouf N, Klein MB, Rourke SB, Rachlis A, Hogg RS, Montaner JS; CANOC Collaboration.

J Int AIDS Soc. 2015 Oct 5;18:20024. doi: 10.7448/IAS.18.1.20024. eCollection 2015.

12.

Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare.

Tapp C, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg RS, Montaner J, Wood E.

BMC Infect Dis. 2011 Apr 6;11:86. doi: 10.1186/1471-2334-11-86.

13.

Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.

Antiretroviral Therapy Cohort Collaboration (ART-CC).

Antivir Ther. 2015;20(1):21-8. doi: 10.3851/IMP2768. Epub 2014 Mar 27.

PMID:
24675571
14.

Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.

Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthuis PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Lau B, Althoff KN, Crane HM, Collier AC, Samji H, Thorne JE, Gill MJ, Klein MB, Martin JN, Rodriguez B, Rourke SB, Gange SJ; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS.

Clin Infect Dis. 2013 Apr;56(8):1174-82. doi: 10.1093/cid/cit003. Epub 2013 Jan 11.

15.

The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso.

Penot P, Héma A, Bado G, Kaboré F, Soré I, Sombié D, Traoré JR, Guiard-Schmid JB, Fontanet A, Slama L, Bruno Sawadogo A, Laurent C.

J Int AIDS Soc. 2014 Jan 15;17:18646. doi: 10.7448/IAS.17.1.18646. eCollection 2014.

16.

Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.

Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration.

HIV Med. 2011 Jul;12(6):352-60. doi: 10.1111/j.1468-1293.2010.00890.x. Epub 2010 Nov 8.

17.

Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.

Kuhn L, Semrau K, Ramachandran S, Sinkala M, Scott N, Kasonde P, Mwiya M, Kankasa C, Decker D, Thea DM, Aldrovandi GM.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):132-6. doi: 10.1097/QAI.0b013e3181ab6d5e.

18.

The feasibility of an intensive case management program for injection drug users on antiretroviral therapy in St. Petersburg, Russia.

Shaboltas AV, Skochilov RV, Brown LB, Elharrar VN, Kozlov AP, Hoffman IF.

Harm Reduct J. 2013 Sep 5;10:15. doi: 10.1186/1477-7517-10-15.

19.

Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users.

Kerr T, Marshall BD, Milloy MJ, Zhang R, Guillemi S, Montaner JS, Wood E.

Drug Alcohol Depend. 2012 Jul 1;124(1-2):108-12. doi: 10.1016/j.drugalcdep.2011.12.019. Epub 2012 Jan 14.

20.

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA.

AIDS. 2008 Nov 30;22(18):2481-92. doi: 10.1097/QAD.0b013e328318f130.

Supplemental Content

Support Center